Safety and effectiveness of disease-modifying therapies after switching from natalizumab.

Maya ZeineddineRaed Al-RoughaniSamar Farouk AhmedSamia KhouryNabil El-AyoubiAkram Al-MahdawiJaber Al-KhabouriAbdullah Al-AsmiAmina ChentoufJihad S Inshasi Riadh GoudierSaloua MrabetNevin ShalabyJoelle MassouhFarah Mohamed Ramzy Hasan MohamedAmal Al-HajjePascale SalamehHani DimassiFarid BoumedieneBassem Yamout

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)

Our study shows superior effectiveness of rituximab/ocrelizumab and alemtuzumab compared with fingolimod in stable patients switching from NTZ due to JC virus antibody positivity.

Keyphrases

multiple sclerosis
end stage renal disease
randomized controlled trial
systematic review
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
patient reported